QCI Asset Management Inc. NY Has $15.29 Million Position in Bristol-Myers Squibb Co (BMY)

QCI Asset Management Inc. NY grew its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 239,865 shares of the biopharmaceutical company’s stock after acquiring an additional 8,099 shares during the quarter. Bristol-Myers Squibb comprises 1.7% of QCI Asset Management Inc. NY’s holdings, making the stock its 24th largest holding. QCI Asset Management Inc. NY’s holdings in Bristol-Myers Squibb were worth $15,289,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AllSquare Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb during the third quarter valued at approximately $134,000. CIBC Asset Management Inc increased its holdings in shares of Bristol-Myers Squibb by 1.4% during the third quarter. CIBC Asset Management Inc now owns 151,852 shares of the biopharmaceutical company’s stock valued at $9,679,000 after acquiring an additional 2,054 shares in the last quarter. Dividend Assets Capital LLC increased its holdings in shares of Bristol-Myers Squibb by 33.5% during the third quarter. Dividend Assets Capital LLC now owns 17,670 shares of the biopharmaceutical company’s stock valued at $1,126,000 after acquiring an additional 4,435 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in shares of Bristol-Myers Squibb by 334.5% during the third quarter. First Eagle Investment Management LLC now owns 49,229 shares of the biopharmaceutical company’s stock valued at $3,138,000 after acquiring an additional 37,900 shares in the last quarter. Finally, Cobblestone Capital Advisors LLC NY increased its holdings in shares of Bristol-Myers Squibb by 36.5% during the third quarter. Cobblestone Capital Advisors LLC NY now owns 16,913 shares of the biopharmaceutical company’s stock valued at $1,078,000 after acquiring an additional 4,518 shares in the last quarter. Hedge funds and other institutional investors own 69.70% of the company’s stock.

In other news, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Co (NYSE BMY) traded down $2.52 during mid-day trading on Monday, reaching $60.96. The company’s stock had a trading volume of 22,946,534 shares, compared to its average volume of 6,640,000. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a twelve month low of $50.36 and a twelve month high of $66.10. The stock has a market capitalization of $99,770.00, a PE ratio of 24.00, a P/E/G ratio of 2.19 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The business’s revenue was up 3.9% on a year-over-year basis. equities research analysts forecast that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date of this dividend was Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is currently 62.99%.

Several brokerages recently issued reports on BMY. Vetr raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price on the stock in a research report on Thursday. Credit Suisse Group set a $62.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Piper Jaffray Companies reaffirmed a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Zacks Investment Research raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday, January 19th. Finally, Citigroup lifted their target price on Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $65.38.

TRADEMARK VIOLATION NOTICE: “QCI Asset Management Inc. NY Has $15.29 Million Position in Bristol-Myers Squibb Co (BMY)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/05/qci-asset-management-inc-ny-acquires-8099-shares-of-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply